Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A systematic review of the use of quality-of-life instruments in randomised controlled trials of psoriasis

Ali, Faraz, Cueva, A.C., Vyas, J., Atwan, A.A., Salek, M.S., Finlay, Andrew and Piguet, Vincent 2017. A systematic review of the use of quality-of-life instruments in randomised controlled trials of psoriasis. British Journal of Dermatology 176 (3) , pp. 577-593. 10.1111/bjd.14788

[thumbnail of AYF  FA A systematic review of the use of quality of life instruments in randomised controlled trials of psoriasis.pdf]
PDF - Accepted Post-Print Version
Download (900kB) | Preview


Background Planners of interventional studies in psoriasis face the dilemma of selecting suitable quality of life (QoL) measures. Systematic reviews (SR) have the potential of identifying psychometrically sound measures in a given therapeutic area, whilst guiding the development of practice guidelines. Objectives The aim of this SR was to generate evidence of the use of QoL instruments in randomised controlled trials (RCTs) for interventions in psoriasis. Methods The methodology followed PRISMA guidelines. Six databases were searched with 388 search terms. Abstracts of articles were reviewed independently by two assessors, a third adjudicator resolved any opinion differences. Risk of bias was assessed using the JADAD scale. Results Of 3646 screened publications, 99 articles (100 trials) met eligibility criteria for inclusion, describing research on 33,215 subjects. 33 trials tested topical therapy, 18 systemic, 39 biologics, 9 phototherapy and 10 tested other interventions. The Dermatology Life Quality Index (DLQI) was the most commonly used QoL instrument (number of studies=83, 83%), followed by the Short Form-36 (SF-36) (31, 31%), EuroQoL (EQ-5D) (15, 15%), Psoriasis Disability Index (PDI) (14,14%) and Skindex (5, 5%). There was widespread inconsistency in the way that QoL data was reported. Of the 100 trials identified, 37 reported Minimal Clinically Important Difference (MCID); 32 were for DLQI, 10 for SF-36 and six for EQ-5D. Conclusions QoL measurement is increasingly being reported in RCTs of psoriasis. Formal guidelines are needed for assessment and publishing of QoL data. Researchers should consider whether MCID information is available, and development of MCID data should be encouraged.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Uncontrolled Keywords: Psoriasis, systematic review, quality of life, treatment, DLQI
Publisher: Wiley-Blackwell
ISSN: 0007-0963
Date of First Compliant Deposit: 8 June 2017
Date of Acceptance: 23 May 2016
Last Modified: 22 May 2022 10:16

Citation Data

Cited 43 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics